Cerus Corporation 2013 Form 10-K Summary
Business Context and Reporting Period
Cerus develops and commercializes the INTERCEPT Blood System, designed to inactivate pathogens in donated blood components. Platelet and plasma systems were commercialized primarily in Europe, the CIS, the Middle East and selected other markets; the red blood cell system remained in development. The filing covers the fiscal year ended December 31, 2013, with quarterly information for the fourth quarter and prior-year comparisons.
The plasma PMA was filed with the FDA and entered substantive review. For the platelet system, two of three PMA modules had been submitted, with the final module expected in the second quarter of 2014. European Phase III trials for the red blood cell system and a U.S. Phase II recovery and lifespan study were ongoing.
Financial Performance and Key Metrics
| Metric | 2013 | 2012 | Change |
|---|---|---|---|
| Product revenue | $39.7 million | $36.7 million | 8% increase |
| Gross profit | $17.1 million | $16.1 million | 6% increase |
| Product gross margin | 43% | 44% | Down 1 percentage point |
| Research and development | $15.2 million | $7.6 million | 100% increase |
| Sales, general and administrative | $30.0 million | $25.7 million | 17% increase |
| Operating loss | $28.3 million | $17.3 million | Higher loss |
| Net loss | $43.3 million | $15.9 million | Higher loss |
| Net loss per share | $0.64 | $0.29 | Higher loss per share |
Revenue growth was driven primarily by higher plasma disposable-kit volume and increased illuminator sales, partially offset by weaker distributor performance. The lower product gross margin reflected a greater mix of plasma kits, which had lower margins than platelet kits. The operating margin was approximately negative 71%, and the net margin was approximately negative 109%.
Fourth-quarter 2013 product revenue was $9.2 million, compared with $10.5 million in fourth-quarter 2012. Fourth-quarter gross profit was $4.3 million, operating loss was $7.8 million and net loss was $5.9 million.
Net cash used in operating activities increased to $26.8 million from $13.9 million. The increase reflected higher operating expenditures, increased accounts receivable and inventory investment. Net cash used in investing activities was $29.1 million, primarily because proceeds from the 2013 equity offering were invested in short-term securities.
At December 31, 2013, cash and cash equivalents were $29.5 million, short-term investments were $28.2 million, working capital was $38.7 million and total assets were $83.4 million. Total stockholders’ equity was $42.8 million.
Total debt was $3.4 million, consisting of borrowings under a Comerica revolving line of credit due in 2014. The $5.0 million growth capital loan was repaid in April 2013. The revolving line was scheduled to mature on June 30, 2014 and was subject to minimum cash and revenue covenants; the company reported compliance at year-end.
Material Changes Versus the Prior Comparable Period
- Product revenue increased 8%, but management described 2013 growth as weaker than expected because of declining performance by certain distributors.
- Research and development spending doubled to $15.2 million, reflecting red blood cell clinical development and U.S. platelet and plasma PMA activities.
- SG&A increased 17% due to corporate services and preparation for a potential U.S. commercial launch.
- Net loss increased substantially, primarily because of a $15.1 million non-cash loss from revaluation of warrant liabilities, compared with a $2.1 million non-cash gain in 2012.
- Warrant liability increased to $20.4 million from $5.9 million, largely because of the higher common-stock price and warrant valuation assumptions.
- Equity financing provided $61.4 million of net proceeds, including $38.0 million from an underwritten offering and $23.5 million from Cantor at-the-market sales. Approximately 5.4 million shares were sold under the Cantor agreement.
- Inventory increased to $13.1 million from $10.2 million, while accounts receivable increased to $6.1 million from $4.4 million.
- The manufacturing and supply agreement with Fresenius was amended effective January 1, 2014, establishing specified purchase commitments and fixed pricing with potential volume-based price reductions through 2018.
Guidance, Outlook, Commentary, Risks and Unusual Items
Management expected 2014 product revenue to remain relatively flat with 2013, with a disproportionate negative impact anticipated in the first half as distributor territories transitioned to new partners or potentially to direct sales. Management expected these changes could temporarily reduce kit volumes and increase operating resources, but could improve pricing, margins and operating contribution over time.
Research and development spending was expected to increase as clinical trials and regulatory submissions continued. Management stated that available cash, product receipts and access to debt were expected to fund requirements for at least the next twelve months, but the company remains dependent on additional capital unless it achieves materially higher revenue and positive operating cash flow. Additional capital will be required to complete red blood cell development and pursue regulatory approvals.
- U.S. regulatory approval remained uncertain. The FDA could require additional clinical trials, manufacturing remediation, post-marketing studies or narrower product indications.
- The company relies heavily on third-party manufacturers, particularly Fresenius, and has limited qualified alternative suppliers. Supply interruptions, component nonconformities, product expirations or recalls could affect sales and margins.
- Customer and revenue concentration was significant: Movaco represented 18% and the French blood service represented 17% of 2013 product revenue.
- The products do not inactivate all pathogens, including prions and certain non-enveloped viruses, which may limit adoption and create product-liability exposure.
- Competition includes alternative pathogen-reduction systems, diagnostic testing and established blood-safety technologies. Octapharma had already received FDA approval for treated plasma before Cerus’s U.S. product approval.
- Royalty obligations to Fresenius were 10% of platelet product sales and 3% of plasma product sales; 2013 royalty payments were $3.0 million.
- Contractual obligations totaled $11.2 million, including $4.7 million of minimum purchase commitments, $3.5 million of debt and $1.9 million of operating leases.
- The filing reports no off-balance-sheet arrangements and no material legal proceedings.
The 2013 financial statements received an unqualified audit opinion. Management and the auditor concluded that internal control over financial reporting was effective as of December 31, 2013.
Important Facts for Investors to Verify
- Progress, timing, deficiencies and potential additional clinical requirements for the FDA plasma and platelet PMAs.
- Cash burn, revolving-credit maturity and covenant compliance, including the company’s ability to fund operations and development after June 2014.
- 2014 revenue performance during distributor transitions and any shift toward direct sales.
- Gross-margin impact from product mix, Fresenius pricing terms and minimum purchase commitments.
- Enrollment, safety and efficacy results from the European red blood cell trials and the U.S. Phase II study.
- Potential dilution from additional equity financing, outstanding warrants and equity compensation. Approximately 5.9 million warrants remained outstanding at year-end.
- Customer concentration, foreign-exchange exposure and reliance on sole-source or limited-source suppliers.